Ajanta Pharma views Research and Development as a vital component of business strategy that will provide a long-term competitive advantage. Our R&D facility Advent has more than 150 diligent and committed scientists. Advent, located in Mumbai, houses a range of state-of -the-art equipment for formulation development, working on different dosage forms ranging from topical creams, ophthalmological preparations, nasal sprays and dry powder inhalers to name a few. We have an equally well equipped API lab at Advent to synthesize high value APIs for some of our key products.
Our R&D hub covers an area of 30,000 sq feet (2,800 sq metres) and is fully equipped with modern amenities and technology for accessing reference material, environmental monitoring, data collection & analysis, record keeping and archiving. A separate Regulatory Affairs team works closely with R&D, Manufacturing and Quality Assurance teams to compile dossiers for submission to various Ministries of Health and / or respective FDAs. Our team is provided with a conducive environment to nurture excellence and innovation that is most essential to develop complex and challenging first-time combination products and also first-to-launch generic products in our focus therapeutic segments.The R&D team is completely involved in any project from concept to Phase IV study tracking market acceptability and after-launch status.
Few of our notable R&D achievements are in the segment of anti-malarial with our flagship brand, ARTEFAN; the first generic product to have been pre-qualified by the World Health Organization (WHO), Geneva. Our other key brands include KAMAGRA (Sildenafil Citrate) & APCALIS-SX (Tadalafil), both used in the treatment of Male Erectile Dysfunction. These are available in the conventional tablet as well as in an innovative "jelly" form which is the world's first of its kind dosage form for this molecule.